Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Qing Liu"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gastrointestinal Cancer
Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer: The Kailuan Study
Xiangming Ma, Haozhe Cui, Miaomiao Sun, Qian Liu, Xining Liu, Guangjian Li, Yaochen Wei, Qingjiang Fu, Siqing Liu, Liying Cao
Cancer Res Treat. 2021;53(4):1113-1122.   Published online January 19, 2021
DOI: https://doi.org/10.4143/crt.2020.817
AbstractAbstract PDFPubReaderePub
Purpose
The influence of fasting blood glucose (FBG) and cholesterolemia primary liver cancer (PLC) in china was analyzed via a large prospective cohort study based on a community population, and the combined effects between them were investigated.
Materials and Methods
Overall, 98,936 staff from the Kailuan Group who participated in and finished physical examinations between 2006 and 2007 were included in the cohort study. Their medical information was collected and they were followed up after examination. The correlations of serum FBG or TC with PLC were analyzed. Then, we categorized all staff into four groups: normal FBG/ non-hypocholesterolemia, normal FBG/hypocholesterolemia, elevated FBG/non-hypocholesterolemia, elevated FBG/hypocholesterolemia and normal FBG/ non-hypocholesterolemia was used as a control group. The combined effects of elevated FBG and hypocholesterolemia with PLC were analyzed using the Age-scale Cox proportional hazard regression model.
Results
During 1,134,843.68 person*years follow up, a total of 388 PLC cases occured. We found the elevated FBG and hypocholesterolemia increases the risk for PLC, respectively. Compared with the non-hypocholesterolemia/normal FBG group, the risk of PLC was significantly increased in the non-hypocholesterolemia/elevated FBG group (HR=1.19,95%CI 0.88–1.62) and hypocholesterolemia/normal FBG group (HR=1.53,95%CI 1.19–1.97), and in the hypocholesterolemia/elevated FBG group (HR=3.16 95%CI2.13-4.69). And, a significant interaction effect was found of FBG and TC on PLC. All results were independent from the influence of liver disease.
Conclusion
Elevated serum FBG and hypocholesterolemia are risk factors for PLC, especially when combined. Thus, for the prevention and treatment of PLC, serum FBG and TC levels should be investigated.

Citations

Citations to this article as recorded by  
  • The role of glucose-6-phosphatase activity in glucose homeostasis and its potential for diabetes therapy
    Lay Shuen Tan, Hwee Hui Lau, Essam M. Abdelalim, Chin Meng Khoo, Richard M. O’Brien, E. Shyong Tai, Adrian Kee Keong Teo
    Trends in Molecular Medicine.2025; 31(2): 152.     CrossRef
  • Association between Metabolically Healthy Status and Risk of Gastrointestinal Cancer
    Haozhe Cui, Fei Tian, Yongliang Chen, Xiangming Ma
    Cancer Research and Treatment.2024; 56(1): 238.     CrossRef
  • Identification of structural motifs critical for human G6PC2 function informed by sequence analysis and an AlphaFold2-predicted model
    Emily M. Hawes, Derek P. Claxton, James K. Oeser, Richard M. O’Brien
    Bioscience Reports.2024;[Epub]     CrossRef
  • Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population
    Matthieu Wargny, Thomas Goronflot, Antoine Rimbert, Jérôme Boursier, Sofiane Kab, Joseph Henny, Antoine Lainé, Christophe Leux, Sarra Smati, Samy Hadjadj, Cédric Le May, Marcel Goldberg, Marie Zins, Bertrand Cariou
    Journal of Hepatology.2024; 80(6): 846.     CrossRef
  • Biochemical and metabolic characterization of a G6PC2 inhibitor
    Emily M. Hawes, Mohsin Rahim, Zeinab Haratipour, Abigail R. Orun, Margaret L. O'Rourke, James K. Oeser, Kwangho Kim, Derek P. Claxton, Ray D. Blind, Jamey D. Young, Richard M. O'Brien
    Biochimie.2024; 222: 109.     CrossRef
  • Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors
    Hao Li, Shuai Wang, Zhengqiang Yang, Xianwei Meng, Meng Niu
    Bioactive Materials.2024; 36: 376.     CrossRef
  • Association between transitions in metabolic health and colorectal cancer across categories of body size phenotype: a prospective cohort study
    Qian Liu, Fei Si, Yuntao Wu, Jing Yu
    Obesity.2024; 32(10): 1948.     CrossRef
  • Prognostic value of AFP-L3 and Des-γ-carboxy prothrombin in advanced primary liver cancer treated with Sorafenib and transarterial chemoembolization
    Shiwen Tang
    American Journal of Translational Research.2024; 16(9): 5004.     CrossRef
  • Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease
    Dongna Zhao, Haozhe Cui, Zhiqiang Shao, Liying Cao
    Annals of Hepatology.2023; 28(4): 100726.     CrossRef
  • Fasting plasma glucose and alanine aminotransferase on the risk of hepatocellular carcinoma: A nested case-control study
    Lizhen Zhang, Zhongge Wang, Ruirui Chen, Zhiyuan Cheng, Jingli Yang, Jing Li, Siyu Li, Yarong Chen, Lulu Xu, Yujia Hu, Yana Bai
    Cancer Epidemiology.2023; 84: 102362.     CrossRef
  • Lipids, cholesterols, statins and liver cancer: a Mendelian randomization study
    Zicheng Liang, Zhen Zhang, Xiaoning Tan, Puhua Zeng
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Triglyceride-glucose index associated with the risk of cardiovascular disease: the Kailuan study
    Qian Liu, Haozhe Cui, Yihan Ma, Xu Han, Zhiwei Cao, Yuntao Wu
    Endocrine.2022; 75(2): 392.     CrossRef
  • Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study
    Haozhe Cui, Qian Liu, Yuntao Wu, Liying Cao
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study
    Li Liu, Zhenguo Wu, Yifan Zhuang, Yerui Zhang, Huiliang Cui, Fanghong Lu, Jie Peng, Jianmin Yang
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • 6,743 View
  • 121 Download
  • 13 Web of Science
  • 14 Crossref
Close layer
Immunotherapy
The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
Si-Qi Tang, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Lei Chen, Yuan Zhang, Ying Guo, Qing Liu, Ying Sun, Cheng Xu, Jun Ma
Cancer Res Treat. 2021;53(2):339-354.   Published online November 6, 2020
DOI: https://doi.org/10.4143/crt.2020.790
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear.
Materials and Methods
Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.
Results
Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).
Conclusion
This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.

Citations

Citations to this article as recorded by  
  • Oral and cutaneous immune‐related adverse events in cancer patients: Prevalence and overall survival
    Osias Vieira de Oliveira Filho, Ivana Lameiras Gibbons, Yuri de Lima Medeiros, Thiago Bueno de Oliveira, Nathaniel Simon Treister, Fabio Abreu Alves
    Oral Diseases.2025; 31(1): 278.     CrossRef
  • Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system
    Naoto Okada, Tomoyuki Yanagi, Takaaki Sasaki, Miho Tamura, Masakazu Ozaki, Atsuyuki Saisyo, Takashi Kitahara
    International Journal of Cancer.2025; 156(2): 293.     CrossRef
  • A Case of Olmesartan-associated Gastritis Observed Over Time
    Mizuho Fujisawa, Tetsuya Yoshizaki, Satoshi Urakami, Risa Ashizaki, Eri Nishikawa, Hiroshi Tanabe, Shinya Hoki, Ryosuke Ishida, Hitomi Hori, Chise Ueda, Hirofumi Abe, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama
    Internal Medicine.2025;[Epub]     CrossRef
  • The use of peripheral blood biomarkers for predicting the risk of immune-related adverse events in immune checkpoint inhibitor therapy
    Louise E Duvall
    Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2025;[Epub]     CrossRef
  • Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a Multinational Association for Supportive Care in Cancer modified Delphi survey
    Julia Lai-Kwon, Claudia Rutherford, Stephanie Best, Hope S. Rugo, Christina H. Ruhlmann, Michael Jefford
    Supportive Care in Cancer.2025;[Epub]     CrossRef
  • Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer
    Leila-Sophie Otten, Alessandra I. G. Buma, Berber Piet, Rob ter Heine, Michel M. van den Heuvel, Valesca P. Retèl
    PharmacoEconomics - Open.2025;[Epub]     CrossRef
  • Clinical and economic impact of the advanced practice nurse in lung cancer patients receiving immunotherapy-based treatments: A quantitative study
    Jorgina Serra-López, Clara Pujol-Besora, Sergio Martínez-Recio, Andrés Barba Joaquín, Mariona Riudavets Melià, Ivana Sullivan, Jordi Torralbas-Ortega, Gina Lladó-Jordan, Margarita Majem, Maria-Antonia Martínez-Momblan
    European Journal of Oncology Nursing.2025; 74: 102809.     CrossRef
  • Long-term immune related adverse events
    Leo Plaçais, Olivier Lambotte
    Current Opinion in Oncology.2025; 37(2): 142.     CrossRef
  • Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study
    Jonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, Laura Duzzi, Emily Narten, Johanna Aurich, Janin Thomas, Lea Grote‐Levi, Susann Mahjoub, Dominik Berliner, Thomas Wirth, Heiko Golpon, Benjamin‐Alexander Bollmann, Imke Von Wasilewski, Ralf Gutzmer, Florian
    Cancer Medicine.2025;[Epub]     CrossRef
  • Application of Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma: Current Status, Challenges, and Future Directions
    Lingxiang Ran, Rui Zhao, Yu Li, Benfan Lin, Zhen Yang, Yuanyin Teng, Jingyi Li, Shi Wang, Hsu Yi Liang, Guangmo Hu
    AI Med.2025; 1(1): 1.     CrossRef
  • Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
    Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Xingyu Wei, Fei Li, Dehua Liao
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Challenges and opportunities in single-domain antibody-based tumor immunotherapy
    Xiaozhi Xi, Shasha Guo, Yuchao Gu, Xuekai Wang, Qiang Wang
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; : 189284.     CrossRef
  • Immune checkpoint inhibitor–related adverse events: Real-world experience from a single veterans’ affairs medical center
    Samantha Benz, Katherine A Sherman, Constantin A Dasanu, Juliana Alvarez-Argote
    Journal of Oncology Pharmacy Practice.2024; 30(4): 697.     CrossRef
  • Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors
    Kremena Petrova Trichkova, Franziska Görtler, Line Bjørge, Cornelia Schuster
    Cancers.2024; 16(2): 250.     CrossRef
  • Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
    Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía,
    Gastroenterología y Hepatología.2024; 47(4): 401.     CrossRef
  • Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
    Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandí
    Revista Española de Enfermedades Digestivas.2024;[Epub]     CrossRef
  • Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis
    Sangwon Shin, Jimin Moon, Chiyoon Oum, Seulki Kim, Soo Ick Cho, Yoojoo Lim, Chan-Young Ock, Seunghwan Shin
    BMC Cancer.2024;[Epub]     CrossRef
  • A case of Stiff-person syndrome with muscle tonicity of the extremities and neck after use of Dulvalumab for lung adenocarcinoma
    Takashi Inoue, Kei Oiwa, Kazuhiro Horiuchi
    Rinsho Shinkeigaku.2024; 64(3): 176.     CrossRef
  • Clinical and translational attributes of immune-related adverse events
    Karijn P. M. Suijkerbuijk, Mick J. M. van Eijs, Femke van Wijk, Alexander M. M. Eggermont
    Nature Cancer.2024; 5(4): 557.     CrossRef
  • Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach
    Desirèe Speranza, Mariacarmela Santarpia, Francesco Luppino, Fausto Omero, Enrica Maiorana, Mariacarmela Cavaleri, Elena Sapuppo, Vincenzo Cianci, Alessia Pugliese, Vito Racanelli, Giulia Maria Camerino, Carmelo Rodolico, Nicola Silvestris
    Expert Opinion on Drug Safety.2024; 23(11): 1405.     CrossRef
  • Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation
    Arielle Elkrief, Nicholas R. Waters, Natalie Smith, Angel Dai, John Slingerland, Nathan Aleynick, Binita Febles, Pooja Gogia, Nicholas D. Socci, Melissa Lumish, Paul A. Giardina, Jamie E. Chaft, Juliana Eng, Robert J. Motzer, Robin B. Mendelsohn, Kate A.
    Cancer Immunology Research.2024; 12(3): 308.     CrossRef
  • Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
    Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía,
    Gastroenterología y Hepatología (English Edition).2024; 47(4): 401.     CrossRef
  • Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity
    静宜 任
    Advances in Clinical Medicine.2024; 14(03): 284.     CrossRef
  • Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
    Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, David Balakirouchenane, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Marie-Claire Bretagne, Joe-Elie Salem, Xavier Declèves, Michel Vidal, Nora Kramkimel, Sarah Guegan, Selim Aractingi, Olivier Hui
    British Journal of Cancer.2024; 130(11): 1866.     CrossRef
  • Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian S
    Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon
    Cancer Treatment Reviews.2024; 126: 102734.     CrossRef
  • Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury
    Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka
    Kanzo.2024; 65(6): 268.     CrossRef
  • Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
    Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka
    Hepatology Research.2024; 54(8): 719.     CrossRef
  • Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?
    Mohamed Mahmoud El-Sayed, Julia Raffaella Bianco, YiJing Li, Zsolt Fabian
    Cells.2024; 13(12): 1071.     CrossRef
  • Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer
    O Karhan, Y Sezgin, S Ileri, S Tunc
    Nigerian Journal of Clinical Practice.2024; 27(6): 800.     CrossRef
  • Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis
    Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, T
    Cancer Medicine.2024;[Epub]     CrossRef
  • Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
    Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds,
    The Lancet Oncology.2024; 25(8): 1053.     CrossRef
  • Selecting Immune Checkpoint Inhibitor Side Effects for Real-Time Monitoring in Routine Cancer Care: A Modified Delphi Study
    Julia Lai-Kwon, Michael Jefford, Stephanie Best, Iris Zhang, Claudia Rutherford
    JCO Oncology Practice.2024; 20(12): 1663.     CrossRef
  • Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis
    Stephanie van der Leij, Karijn P.M. Suijkerbuijk, Medard F.M. van den Broek, Gerlof D. Valk, Jan Willem Dankbaar, Hanneke M. van Santen
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action
    Antonio Malvaso, Pierpaolo Giglio, Luca Diamanti, Matteo Gastaldi, Elisa Vegezzi, Andrea Pace, Paola Bini, Enrico Marchioni
    Brain Sciences.2024; 14(8): 764.     CrossRef
  • Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy
    Gerald J. Sun, Gustavo Arango-Argoty, Gary J. Doherty, Damian E. Bikiel, Dejan Pavlovic, Allen C. Chen, Ross A. Stewart, Zhongwu Lai, Etai Jacob
    iScience.2024; 27(9): 110634.     CrossRef
  • Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer
    Annie Xiao, Xiaochen Li, Chongkai Wang, Marwan Fakih
    Clinical Colorectal Cancer.2024;[Epub]     CrossRef
  • Toxicity in the era of immune checkpoint inhibitor therapy
    Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary, Sayan Alekseev, Anisha B. Patel, Yuanteng Jeff Li, Ajay Sheshadri, Monica E. Loghin, Karin Woodman, Ashley E. Aaroe, Sarah Hamidi, Priyanka Chandrasek
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors
    Christopher J. Hoimes, Suzanne McGettigan, Lee Schwartzberg
    The American Journal of Medicine.2024; 137(12): 1200.     CrossRef
  • Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study
    Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada
    Journal of Pharmaceutical Health Care and Sciences.2024;[Epub]     CrossRef
  • Melittin-incorporated nanomedicines for enhanced cancer immunotherapy
    Xuefeng Duan, Haoyang Zou, Jiazhen Yang, Shixian Liu, Tianmin Xu, Jianxun Ding
    Journal of Controlled Release.2024; 375: 285.     CrossRef
  • Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic review
    Yoni Byron, Sonya Yegorova‐Lee, Martin Tio
    Cancer Medicine.2024;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver
    Luca Marzi, Andrea Mega, Chiara Turri, Stefano Gitto, Federica Ferro, Gilbert Spizzo
    International Journal of Molecular Sciences.2024; 25(21): 11676.     CrossRef
  • Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy
    Iris Teruel, Eva Castellà, Sabela Recalde, Gemma Viñas, Anna Petit, Macedonia Trigueros, Eva Martínez-Balibrea, Eudald Felip, Milana Bergamino, Adrià Bernat-Peguera, Beatriz Cirauqui, Vanesa Quiroga, Angelica Ferrando-Díez, Anna Pous, Assumpció López, Lai
    International Journal of Molecular Sciences.2024; 25(22): 12241.     CrossRef
  • Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma
    Brooke Kielkowski, Diana Mansour, Brooke Ebbert, Kelsea Seago, Sijin Wen, Hang Li, Christine Barrett
    Journal of Oncology Pharmacy Practice.2024;[Epub]     CrossRef
  • Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer
    Cynthia X. Wei, Sandra K. Althouse, Hirva Mamdani, Nasser H. Hanna, Greg A. Durm
    Clinical Lung Cancer.2024;[Epub]     CrossRef
  • Safety of sequential immune checkpoint inhibitors after prior immune therapy
    Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit, Brigitte Gil, Natalie Dal’Bo, Lewena Maher, Seanna Reilly Daves, Stephanie McDonald, Krishna S. Gunturu
    Journal of Cancer Research and Clinical Oncology.2023; 149(6): 2375.     CrossRef
  • The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex
    Murielle N. Wahli, Stefanie Hayoz, Dennis Hoch, Christoph O. Ryser, Michèle Hoffmann, Amina Scherz, Birgit Schwacha-Eipper, Simon Häfliger, Julian Wampfler, Martin D. Berger, Urban Novak, Berna C. Özdemir
    Journal of Cancer Research and Clinical Oncology.2023; 149(7): 3847.     CrossRef
  • Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
    Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, Ayako Furugen, Yoh Takekuma, Naofumi Shinagawa, Yasushi Shimizu, Hirotoshi Dosaka-Akita, Mitsuru Sugawara, Masaki Kobayashi
    Journal of Cancer Research and Clinical Oncology.2023; 149(4): 1659.     CrossRef
  • Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis
    Qian Guo, Jian Gao, Hui Guo, Jun Xie, Jingmin Cheng
    International Immunopharmacology.2023; 114: 109490.     CrossRef
  • Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis
    Su Jeong Song, Yun-Kyoung Song, Mihwa Jang, Eunjeong Shin, Sung Yun Suh, Yoon Sook Cho, Ju-Yeun Lee, Jung Mi Oh
    Targeted Oncology.2023; 18(1): 147.     CrossRef
  • Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis
    Qian Guo, Jin Ning Zhao, Ting Liu, Jian Gao, Hui Guo, Jing Min Cheng
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
    Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. K. Mok, Martin Reck, Gene G. Finley, Monika D. Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard J. West
    JAMA Oncology.2023; 9(4): 527.     CrossRef
  • Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment
    Gaetano Maria Russo, Anna Russo, Fabrizio Urraro, Fabrizio Cioce, Luigi Gallo, Maria Paola Belfiore, Angelo Sangiovanni, Stefania Napolitano, Teresa Troiani, Pasquale Verolino, Antonello Sica, Gabriella Brancaccio, Giulia Briatico, Valerio Nardone, Alfons
    Diagnostics.2023; 13(4): 793.     CrossRef
  • Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
    Juyue Zhou, Zhonghai Du, Jie Fu, Xiuxiu Yi
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report
    Nidhi Goel, Monica D. Levine, Laura M. Chambers, Christa I. Nagel
    Gynecologic Oncology Reports.2023; 47: 101174.     CrossRef
  • Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
    Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner
    Journal for ImmunoTherapy of Cancer.2023; 11(3): e006398.     CrossRef
  • Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients
    Berna C. Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, Pierre Monney, Sabina A. Guler, Uyen Huynh-Do, Guido Stirnimann, Lucia Possamai, Roman Trepp, Robert Hoepner, Anke Salmen, Camille L. Gerard, Petr Hruz, Lisa Christ, Sacha I. Rothschild
    Cancer Immunology, Immunotherapy.2023; 72(7): 1991.     CrossRef
  • Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features
    Julianna Martel, Hannah L. Hanania, Anisha B. Patel
    Human Pathology.2023; 140: 144.     CrossRef
  • Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity
    Catherine C. Fahey, Thomas J. Gracie, Douglas B. Johnson
    Expert Review of Anticancer Therapy.2023; 23(7): 673.     CrossRef
  • Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Rafael Morales-Barrera, Guillermo Villacampa, Natalia Vidal, Mariona Figols, Julia Giner, Teresa Bonfill, Cristina Suárez, Nely Díaz, Joaquín Mateo, Macarena González, Montserrat Domenech, Javier Puente, Joan Carles
    Clinical and Translational Oncology.2023; 25(12): 3556.     CrossRef
  • The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review
    Julia Lai-Kwon, Jordan E. Cohen, Karolina Lisy, Claudia Rutherford, Afaf Girgis, Ethan Basch, Michael Jefford
    JCO Clinical Cancer Informatics.2023;[Epub]     CrossRef
  • Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
    Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, Hiroki Kubota, Yusuke Noda, Maria Aoki, Yoshinobu Moritoki, Satoshi Nozaki, Satoshi Kurokawa, At
    International Journal of Urology.2023; 30(10): 866.     CrossRef
  • Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy
    Shu-Jung Hsu, Yen-Cheng Chao, Xia-Hui Lin, Hua-Hua Liu, Yang Zhang, Wei-Feng Hong, Mao-Pei Chen, Xin Xu, Lan Zhang, Zheng-Gang Ren, Shi-Suo Du, Rong-Xin Chen
    Clinical and Experimental Immunology.2023; 212(3): 239.     CrossRef
  • First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
    Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Céleste Lebbé, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen B
    Journal of Clinical Oncology.2023; 41(23): 3917.     CrossRef
  • Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
    Hyo Sook Han, Praveen Vikas, Ricardo L.B. Costa, Nusrat Jahan, Ammanuel Taye, Erica M. Stringer-Reasor
    American Society of Clinical Oncology Educational Book.2023;[Epub]     CrossRef
  • An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management
    Yiyu Cheng, Fangmei Ling, Junrong Li, Yidong Chen, Mingyang Xu, Shuang Li, Liangru Zhu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma
    Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Tetsuya Tsuchida, Ai Yoshida, Takako Yamada, Akira Komoto
    The Journal of Dermatology.2023; 50(9): 1108.     CrossRef
  • Real‐world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors
    Srilatha Dasari, William Tse, Jiasheng Wang
    British Journal of Haematology.2023; 202(6): 1205.     CrossRef
  • Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors
    André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, Stellio Giacomini, Sébastien Bugeia, Garance Gutknecht, Gilliosa Spurrier-Bernard, Veronica Aedo-Lopez, Nuria Mederos, Sofiya Latifyan, Alfredo Addedo, Olivier Michielin, Manuela Eicher
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • CD4 T cells and toxicity from immune checkpoint blockade
    Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y. Chen, Mario Sznol, Ruth Halaban, Aadel A. Chaudhuri, Aaron M. Newman
    Immunological Reviews.2023; 318(1): 96.     CrossRef
  • Anti‑PD1 therapy‑associated distal renal tubular acidosis: A case report
    Xuejia Qiu, Bingnan Ren, Lingzhi Fang, Zhanjun Dong
    Experimental and Therapeutic Medicine.2023;[Epub]     CrossRef
  • Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review
    Minoru Kato, Junji Uchida
    International Journal of Urology.2023; 30(12): 1068.     CrossRef
  • Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab
    Manuel A. Baarslag, Joosje H. Heimovaara, Jessica S.W. Borgers, Koen J. van Aerde, Hans J.P.M. Koenen, Ruben L. Smeets, Pauline L.M. Buitelaar, Dick Pluim, Shoko Vos, Stefanie S.V. Henriet, Jan Willem B. de Groot, Martine van Grotel, Hilde Rosing, Jos H.
    New England Journal of Medicine.2023; 389(19): 1790.     CrossRef
  • Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study
    Kou Masaki, Motoyasu Miyazaki, Hideki Kakimoto, Yuma Fukiage, Haruka Fukue, Akio Nakashima, Osamu Imakyure
    Journal of Clinical Medicine.2023; 12(24): 7564.     CrossRef
  • Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
    Priyatharcini Kejamurthy, K. T. Ramya Devi
    Medical Oncology.2023;[Epub]     CrossRef
  • Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation
    Sara Sheikhbahaei, Charles V. Marcus, Mohammad S. Sadaghiani, Steven P. Rowe, Martin G. Pomper, Lilja B. Solnes
    American Journal of Roentgenology.2022; 218(6): 940.     CrossRef
  • Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation
    Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain
    The Journal of Clinical Pharmacology.2022; 62(4): 532.     CrossRef
  • T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
    Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé B. Steen, Bogdan A. Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, Farnaz Khameneh, Peter K. Harri
    Nature Medicine.2022; 28(2): 353.     CrossRef
  • Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity
    Ka Man Cheung, Therese Yue Man Tsui, James Chung Hang Chow
    Cancer.2022; 128(13): 2549.     CrossRef
  • CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
    Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika
    Journal of Personalized Medicine.2022; 12(6): 888.     CrossRef
  • A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
    Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
    Cancer Research and Treatment.2022; 54(4): 1005.     CrossRef
  • Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
    Ana Cardeña-Gutiérrez, Mónica López Barahona
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy
    Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray
    European Journal of Cancer.2022; 172: 98.     CrossRef
  • Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
    Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, Lucie Heinzerling
    Cancers.2022; 14(13): 3282.     CrossRef
  • Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
    Ben-Max de Ruiter, Jons W. van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, A.H. Maartje Piet, Mila Donker, Tom van der Hulle, Jens Voortman, Jorg R. Oddens, Maarten C.C.M. Hulshof, Adriaan D. Bins
    European Urology.2022; 82(5): 518.     CrossRef
  • Adverse Renal Effects of Anticancer Immunotherapy: A Review
    Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak, Jerzy Chudek
    Cancers.2022; 14(17): 4086.     CrossRef
  • Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
    Nari Kim, Eun Sung Lee, Sang Eun Won, Mihyun Yang, Amy Junghyun Lee, Youngbin Shin, Yousun Ko, Junhee Pyo, Hyo Jung Park, Kyung Won Kim
    Korean Journal of Radiology.2022; 23(11): 1089.     CrossRef
  • Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data
    Jiasheng Wang, Srilatha Dasari, Dina Elantably, Akram Alkrekshi, Yeseong David Kim
    Acta Oncologica.2022; 61(9): 1157.     CrossRef
  • Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
    Chan Kim, Hannah Yang, Ilhwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon
    JAMA Oncology.2022; 8(12): 1825.     CrossRef
  • Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
    Ik Shin Chin, Aman Khan, Anna Olsson-Brown, Sophie Papa, Gary Middleton, Claire Palles
    npj Genomic Medicine.2022;[Epub]     CrossRef
  • The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
    Deniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mus
    Anti-Cancer Drugs.2022;[Epub]     CrossRef
  • Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer
    Lance L. Munn, Triantafyllos Stylianopoulos, Natalie K. Jain, C. Corey Hardin, Melin J. Khandekar, Rakesh K. Jain
    Clinical Cancer Research.2021; 27(10): 2706.     CrossRef
  • Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
    Jonathan T. Hunt, Laura M. Chambers, Meng Yao, Amy Joehlin-Price, Robert Debernardo, Peter G. Rose
    Gynecologic Oncology Reports.2021; 37: 100840.     CrossRef
  • Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy
    Jie Zhang, Zhujiang Dai, Cheng Yan, Daorong Wang, Dong Tang
    Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3639.     CrossRef
  • Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
    Jay M. Lee, Anthony W. Kim, Tomasz Marjanski, Pierre-Emmanuel Falcoz, Masahiro Tsuboi, Yi-Long Wu, Shawn W. Sun, Barbara J. Gitlitz
    JTO Clinical and Research Reports.2021; 2(10): 100221.     CrossRef
  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
    Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael
    Journal of Clinical Oncology.2021; 39(36): 4073.     CrossRef
  • Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
    Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • 14,806 View
  • 702 Download
  • 88 Web of Science
  • 97 Crossref
Close layer
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Xueying Li, He Huang, Bing Xu, Hongqiang Guo, Yingcheng Lin, Sheng Ye, Jiqun Yi, Wenyu Li, Xiangyuan Wu, Wei Wang, Hongyu Zhan, Derong Xie, Jiewen Peng, Yabing Cao, Xingxiang Pu, Chengcheng Guo, Huangming Hong, Zhao Wang, Xiaojie Fang, Yong Zhou, Suxia Lin, Qing Liu, Tongyu Lin
Cancer Res Treat. 2019;51(3):919-932.   Published online October 2, 2018
DOI: https://doi.org/10.4143/crt.2018.230
AbstractAbstract PDFPubReaderePub
Purpose
Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population.
Materials and Methods
Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP- 14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities.
Results
Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ≥ 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21.
Conclusion
R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ≥ 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.

Citations

Citations to this article as recorded by  
  • Prediction of 5‐year overall survival of diffuse large B‐cell lymphoma on the pola‐R‐CHP regimen based on 2‐year event‐free survival and progression‐free survival
    Wan‐Ru Zhang, Xin Liu, Qiu‐Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue‐Ping Liu, Yong‐Wen Song, Hui Fang, Ning‐Ning Lu, Ning Li, Yi‐Rui Zhai, Wen‐Wen Zhang, Shu‐Lian Wang, Fan Chen, Lin Yin, Shu‐Nan Qi, Ye‐Xiong Li
    Cancer Medicine.2024;[Epub]     CrossRef
  • Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
    Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang, Jianda Hu, Huaqing Wang, Hang Su, Zhengming Jin, Wenbin Qian, Chuan Jin, Mingzhi Zhang, Ding Yu, Li Liu, Guoan Chen, Yarong Li, Tao Sun, Jie J
    BMC Cancer.2024;[Epub]     CrossRef
  • Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429/DNMT3A axis
    Weiming LI, Ming GAO, Weili XUE, Xiaoli LI, Yu CHANG, Kaixin ZHANG, Chenyu WEN, Mingzhi ZHANG
    Chinese Journal of Natural Medicines.2024; 22(6): 554.     CrossRef
  • Prophylaxis forPneumocystis cariniipneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
    Xiaojia Huang, Xiaoting Huang, Shen Lin, Shaohong Luo, Liangliang Dong, Dong Lin, Yaping Huang, Chen Xie, Dongni Nian, Xiongwei Xu, Xiuhua Weng
    BMJ Open.2023; 13(3): e068943.     CrossRef
  • Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving S
    Yu Ri Kim, Jin Seok Kim, Won Seog Kim, Hyeon Seok Eom, Deok-Hwan Yang, Sung Hwa Bae, Hyo Jung Kim, Jae Hoon Lee, Suk-Joong Oh, Sung-Soo Yoon, Jae-Yong Kwak, Chul Won Choi, Min Kyoung Kim, Sung Young Oh, Hye Jin Kang, Seung Hyun Nam, Hyeok Shim, Joon Seong
    Cancer Research and Treatment.2023; 55(4): 1355.     CrossRef
  • Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
    Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Dominic Kaddu-Mulindwa, Andreas Viardot, Mathias Witzens-Harig, Judith Dierlamm, Mathias Haenel, Bernd Metzner, Gerald Wulf, Eva Lengfelder, Ulrich B. Keller, Norbert Fr
    HemaSphere.2023; 7(7): e904.     CrossRef
  • Treatment of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Literature Review and Meta-Analysis
    Aleksander Sergeevich Luchinin
    Clinical oncohematology.2022; 15(2): 130.     CrossRef
  • The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients
    Shunfeng Hu, Na Chen, Kang Lu, Changqing Zhen, Xiaohui Sui, Xiaosheng Fang, Ying Li, Yingshu Luo, Xiangxiang Zhou, Xin Wang
    Leukemia & Lymphoma.2021; 62(6): 1335.     CrossRef
  • Primary diffuse large B-cell lymphoma of the fallopian tube treated with a combination of surgery and chemotherapy
    Ye Zhou, Chao Zhang, Yingying Gong, Linqing Yang, Yunfei Wang
    Medicine.2021; 100(3): e24049.     CrossRef
  • Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
    Anuvrat Sircar, Sayan Chowdhury, Amber Hart, William Bell, Satishkumar Singh, Lalit Sehgal, Narendranath Epperla
    International Journal of Molecular Sciences.2020; 21(3): 904.     CrossRef
  • Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
    Jie Zhu, Yong Yang, Jin Tao, Shu-Lian Wang, Bo Chen, Jian-Rong Dai, Chen Hu, Shu-Nan Qi, Ye-Xiong Li
    Leukemia.2020; 34(10): 2576.     CrossRef
  • Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
    Murali Kesavan, Toby A. Eyre, Graham P. Collins
    Current Hematologic Malignancy Reports.2019; 14(4): 207.     CrossRef
  • Immunohistochemical Subtype and Parameters of International Prognostic Index in the New Prognostic Model of Diffuse Large B-Cell Lymphoma
    Svetlana Valer'evna Samarina, A.S. Luchinin, N.V. Minaeva, I.V. Paramonov, D.A. D'yakonov, E.V. Vaneeva, V.A. Rosin, S.V. Gritsaev
    Clinical oncohematology.2019; 12(4): 25.     CrossRef
  • 10,333 View
  • 286 Download
  • 12 Web of Science
  • 13 Crossref
Close layer
Clinicopathologic Characteristics and Prognosis of Tongue Squamous Cell Carcinoma in Patients with and without a History of Radiation for Nasopharyngeal Carcinoma: A Matched Case-Control Study
Peng Zhang, Li Zhang, Hui Liu, Lei Zhao, Yong Li, Jing-Xian Shen, Qing Liu, Meng-Zhong Liu, Mian Xi
Cancer Res Treat. 2017;49(3):695-705.   Published online October 11, 2016
DOI: https://doi.org/10.4143/crt.2016.317
AbstractAbstract PDFPubReaderePub
Purpose
Previous studies reported an association between an increased risk of tongue cancer and radiation treatment for nasopharyngeal carcinoma (NPC). This study compared the clinicopathologic characteristics and outcomes of tongue squamous cell carcinoma (TSCC) in patients with and without a history of radiotherapy for NPC.
Materials and Methods
From 1965 to 2009, a total of 73 patients were diagnosed with TSCC with a history of radiotherapy for NPC. The patients were matched in a 1:3 ratio with patients with sporadic TSCC according to age, sex, and year of the TSCC diagnosis. The primary endpoint was the overall survival.
Results
The median interval from NPC to TSCC was 82 months. The NPC survivors were more likely to be diagnosed with a more advanced T classification, less likely to have lymph node involvement, and more likely to have the tumor located in the dorsum of the tongue than sporadic TSCC. Regarding the histologic characteristics, the NPC survivors were more likely to have a weak lymphocytic host response, low tumor budding, and low risk of a worse pattern of invasion. The sporadic TSCC patients had a better overall survival (hazard ratio, 0.690; p=0.033) than the NPC survivors. In competing risks analysis, the cumulative incidence functions for the competing event (documented non-tongue cancer death) were significantly higher in the NPC survivors (Gray’s test, p=0.001).
Conclusion
TSCC patients with a history of radiotherapy for NPC appear to have particular clinicopathologic features, a poorer survival, and are more likely to die from non-tongue cancer causes than those with sporadic TSCC.

Citations

Citations to this article as recorded by  
  • Radiotherapy upregulated immune checkpoints contribute to the development of second primary OSCC
    Li Wang, Siyu Wang, Jiayu Zhang, Jianmin Peng, Bin Cheng, Huan Li, Qinchao Hu
    Oral Diseases.2024; 30(4): 2188.     CrossRef
  • Impact of histopathological parameters in prognosis of oral squamous cell carcinoma
    R. P. Ekanayaka, W. M. Tilakaratne
    Oral Diseases.2024;[Epub]     CrossRef
  • Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma
    James C. H. Chow, Wah Cheuk, William C. S. Cho, Chi-Fai Wong, Dennis W. Y. Au, Anthony H. P. Tam, Rachel C. W. Wong, Jeffrey C. H. Chan, Simon C. C. Law, Roger K. C. Ngan, Kam-Hung Wong, Ka-Man Cheung
    JAMA Network Open.2023; 6(7): e2323890.     CrossRef
  • Clinical characterization of radiation-associated muscle-invasive bladder cancer
    Sybil T. Sha, Edward Christopher Dee, Matthew Mossanen, Brandon A. Mahal, Cierra Zaslowe-Dude, Trevor J. Royce, Michelle S. Hirsch, Guru Sonpavde, Mark A. Preston, Paul L. Nguyen, Kent W. Mouw, Vinayak Muralidhar
    Urology.2021; 154: 208.     CrossRef
  • SPP1 and FN1 are significant gene biomarkers of tongue squamous cell carcinoma
    Xiao-Liang Xu, Hui Liu, Ying Zhang, Su-Xin Zhang, Zhong Chen, Yang Bao, Tian-Ke Li
    Oncology Letters.2021;[Epub]     CrossRef
  • Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma
    Liyuan Dai, Qigen Fang, Peng Li, Junfu Wu, Xu Zhang
    Cancer Research and Treatment.2020; 52(1): 109.     CrossRef
  • Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG
    James C.H. Chow, Anthony H.P. Tam, Ka-Man Cheung, Victor H.F. Lee, Chi-Leung Chiang, Macy Tong, Edwin C.Y. Wong, Alice K.W. Cheung, Sunny P.C. Chan, Jessica W.Y. Lai, Roger K.C. Ngan, Wai-Tong Ng, Anne W.M. Lee, Kwok-Hung Au
    Oral Oncology.2020; 111: 105012.     CrossRef
  • BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma
    Miao Wang, Lu Zhao, Dongdong Tong, Linrui Yang, Hongjie Zhu, Qing Li, Fenghe Zhang
    International Immunopharmacology.2019; 76: 105921.     CrossRef
  • Surgical treatment of early tongue squamous cell carcinoma and patient survival
    Lansheng Zhu, Yanling Wang, Rui Li, Aiqun Liu, Xiaoping Zhang, Chunran Zuo, Xiaoting Xu
    Oncology Letters.2019;[Epub]     CrossRef
  • Keratin 6A gene silencing suppresses cell invasion and metastasis of nasopharyngeal carcinoma via the β‑catenin cascade
    Chuanjun Chen, Huiguo Shan
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Tumour budding in oral squamous cell carcinoma: a meta-analysis
    Alhadi Almangush, Matti Pirinen, Ilkka Heikkinen, Antti A Mäkitie, Tuula Salo, Ilmo Leivo
    British Journal of Cancer.2018; 118(4): 577.     CrossRef
  • The poor outcome of second primary oral squamous cell carcinoma is attributed to Bmi1 upregulation
    Qinchao Hu, Tong Wu, Xiaobing Chen, Huan Li, Zhicheng Du, Yuantao Hao, Jianmin Peng, Shanshan Tai, Ming Song, Bin Cheng
    Cancer Medicine.2018; 7(4): 1056.     CrossRef
  • Clinical analysis of second primary gingival squamous cell carcinoma after radiotherapy
    Xiaoyan Fu, Shuwei Chen, Weichao Chen, Zhongyuan Yang, Ming Song, Hao Li, Huayong Zhang, Fan Yao, Xuan Su, Tianrun Liu, An-Kui Yang
    Oral Oncology.2018; 84: 20.     CrossRef
  • 11,364 View
  • 209 Download
  • 17 Web of Science
  • 13 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP